



ASX ANNOUNCEMENT

30 June 2009

Appointment of Dr Cherrell Hirst as Company Director

The Board of Biomedical company, **Tissue Therapies Limited (ASX: TIS)** has with the greatest of pleasure announced today the appointment of Dr Cherrell Hirst as a Director of the company.

In addition to her distinguished clinical career in the detection and treatment of breast cancer, Dr Hirst has extensive and highly respected achievements in both commercial and not-for-profit organisations. She is currently Deputy Chair and CEO (part time) of Queensland Biocapital Funds and a Director of Peplin, Suncorp Metway, Avant Mutual Group and Avant Insurance Ltd, Impedimed Ltd and Xenome Ltd.

Dr Hirst is also a former Chancellor of the Queensland University of Technology and has served as Director and Chair of multiple commercial, community and government organisations throughout her career.

In recognition of her exceptional contributions to the nation, Dr Hirst has received multiple awards including Officer of the Order of Australia, General Division, 1998; Centenary Medal, 2001; Queenslander of the Year, 1995 and multiple Honorary Doctorates from Australian universities.

The Chairman of Tissue Therapies Ltd, Mr Roger Clarke said, "The Directors of Tissue Therapies are delighted that Dr Hirst has agreed to join the Board. Her substantial commercial and other accomplishments speak for themselves and we look forward to the considerable contribution she will be able to make to Tissue Therapies in the important phase of the company's development as we approach commercial scale production and initial sales of VitroGro® wound healing products."

Further information:

Dr Steven Mercer
CEO, Tissue Therapies Limited
Telephone: +61 (0)7 3839 9938

Email: s.mercer@tissuetherapies.com

About Tissue Therapies Limited

Tissue Therapies Limited is an Australian company developing biomedical technologies for wound healing, tissue repair and various cell culture applications.

The Company has worldwide exclusive rights to commercialise VitroGro®, a technology developed by tissue engineering experts at the Institute for Health and Biomedical Innovation at QUT for enhancing cell growth and migration. VitroGro® has particular commercial applications in wound healing, tissue regeneration, stem cell therapies and other cell culture uses.

Based on its VitroGro® technology, Tissue Therapies is developing more effective medical treatments for wound healing including chronic ulcers and burns,

Tissue Therapies also provides cell culture reagents to enhance the growth of mammalian cells for emerging cell-based therapies, along with research and industrial cell culture markets internationally.

More information: www.tissuetherapies.com